<?xml version='1.0' encoding='UTF-8'?>
<bill xmlns="http://xml.house.gov/schemas/uslm/1.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://xml.house.gov/schemas/uslm/1.0 USLM-1.0.18.xsd" xml:lang="en"><?page 1?><meta><dc:title pagenum="1"> S3201 ENR: Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act</dc:title><dc:publisher>U.S. Senate</dc:publisher><dc:date/><dc:format>text/xml</dc:format><dc:language>EN</dc:language><dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights><dc:creator>Xcential BillDTD to USLM Converter v20200824</dc:creator><property role="congress">One Hundred Sixteenth Congress of the United States of America</property><property role="session">2d Session</property><property role="legis-type">AN ACT</property><property role="legis-num">S. 3201</property><property role="current-chamber">IN THE SENATE OF THE UNITED STATES</property><property role="official-title">To extend the temporary scheduling order for fentanyl-related substances, and for other purposes.</property><property role="docStage">ENR</property><property role="citableAs" value="116s3201enr">116 S. 3201 ENR</property></meta><main id="HC3D145290CCD11EB106309173F13E4C5" name="S3201"><longTitle><content><p>AN ACT</p><p>To extend the temporary scheduling order for fentanyl-related substances, and for other purposes.</p></content></longTitle><enactingFormula>Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,</enactingFormula><section identifier="/s1" id="idCDD497A65404452D9421D504DA4E6A7B" class="bill-dtd-OLC" pagenum="1"><num value="1">Section 1.</num><heading> Short title.</heading><content class="indent0">This Act may be cited as the “<quotedText><shortTitle>Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act</shortTitle></quotedText>”.</content></section><section identifier="/s2" id="id4d77b57748b84cb38a8c05f8f5bf9351" class="bill-dtd-OLC" pagenum="1"><num value="2">Sec. 2.</num><heading> Extension of temporary order for fentanyl-related substances.</heading><content class="indent0">Notwithstanding any other provision of law, section 1308.11(h)(30) of title 21, Code of Federal Regulations, shall remain in effect until May 6, 2021.</content></section><section identifier="/s3" id="ida31f4663c6744aa3ba72708eaf978783" class="bill-dtd-OLC" pagenum="1"><num value="3">Sec. 3.</num><heading> Study and report on impacts of classwide scheduling.</heading><subsection identifier="/s3/a" id="id68d74537386b4dc68936b70035b4a9ea" class="bill-dtd-OLC" pagenum="1"><num value="a">(a)</num><heading> Definition.—</heading><content>In this section, the term “<term>fentanyl-related substance</term>” has the meaning given the term in section 1308.11(h)(30)(i) of title 21, Code of Federal Regulations.</content></subsection><subsection identifier="/s3/b" id="id331e4c11ec1b44788509f33453c2dd37" class="bill-dtd-OLC" pagenum="1"><num value="b">(b)</num><heading> GAO report.—</heading><chapeau>The Comptroller General of the United States shall—</chapeau><paragraph identifier="/s3/b/1" id="id42b7d5c07f0d4500b527beb41b8eead2" class="bill-dtd-OLC" pagenum="1"><num value="1">(1)</num><content> conduct a study of the classification of fentanyl-related substances as schedule I controlled substances under the Controlled Substances Act (<ref href="/us/usc/21/801">21 U.S.C. 801</ref> et seq.), research on fentanyl-related substances, and the importation of fentanyl-related substances into the United States; and</content></paragraph><paragraph identifier="/s3/b/2" id="id64E55C756B3743A18D4DC755D8206E97" class="bill-dtd-OLC" pagenum="1"><num value="2">(2)</num><chapeau> not later than 1 year after the date of enactment of this Act, submit a report on the results of the study conducted under paragraph (1) to—</chapeau><subparagraph identifier="/s3/b/2/A" id="id81DF816C560848E28AC1CC5B6C0F881F" class="bill-dtd-OLC" pagenum="1"><num value="A">(A)</num><content> the Committee on the Judiciary of the Senate;</content></subparagraph><subparagraph identifier="/s3/b/2/B" id="idEBB8ED618B264673992943C2D3EA334A" class="bill-dtd-OLC" pagenum="1"><num value="B">(B)</num><content> the Committee on Health, Education, Labor, and Pensions of the Senate;</content></subparagraph><subparagraph identifier="/s3/b/2/C" id="idBCD117EFEE0B43A5829649C45ECA6F32" class="bill-dtd-OLC" pagenum="1"><num value="C">(C)</num><content> the Caucus on International Narcotics Control of the Senate;</content></subparagraph><subparagraph identifier="/s3/b/2/D" id="idF94A5A081ABC4174847EE6BD5C9C1F20" class="bill-dtd-OLC" pagenum="1"><num value="D">(D)</num><content> the Committee on the Judiciary of the House of Representatives; and</content></subparagraph><subparagraph identifier="/s3/b/2/E" id="idC2E1738CC4234B99B3A6E6AF0D29F530" class="bill-dtd-OLC" pagenum="1"><num value="E">(E)</num><content> the Committee on Energy and Commerce of the House of Representatives.</content></subparagraph></paragraph></subsection><subsection identifier="/s3/c" id="idf86a61ca91f04e3086e5de6612d0ce41" class="bill-dtd-OLC" pagenum="1"><num value="c">(c)</num><heading> Requirements.—</heading><chapeau>The Comptroller General, in conducting the study and developing the report required under subsection (b), shall—</chapeau><paragraph identifier="/s3/c/1" id="id5f5c805a10624567bc03f96d1e8c0694" class="bill-dtd-OLC" pagenum="1"><num value="1">(1)</num><chapeau> evaluate class control of fentanyl-related substances, including—</chapeau><?page 2?><subparagraph identifier="/s3/c/1/A" id="id5b0fe3dbe666425c9e53f5c5f51f63d3" class="bill-dtd-OLC" pagenum="2"><num value="A">(A)</num><content> the definition of the class of fentanyl-related substances in section 1308.11(h)(30)(i) of title 21, Code of Federal Regulations, including the process by which the definition was formulated;</content></subparagraph><subparagraph identifier="/s3/c/1/B" id="idd00b6223c5614e188ce56aac75d57cb0" class="bill-dtd-OLC" pagenum="2"><num value="B">(B)</num><content> the potential for classifying fentanyl-related substances with no, or low, abuse potential, or potential accepted medical use, as schedule I controlled substances when scheduled as a class; and</content></subparagraph><subparagraph identifier="/s3/c/1/C" id="id54414583b9004ce39128ade030746c75" class="bill-dtd-OLC" pagenum="2"><num value="C">(C)</num><content> any known classification of fentanyl-related substances with no, or low, abuse potential, or potential accepted medical use, as schedule I controlled substances that has resulted from the scheduling action of the Drug Enforcement Administration that added paragraph (h)(30) to section 1308.11 of title 21, Code of Federal Regulations;</content></subparagraph></paragraph><paragraph identifier="/s3/c/2" id="idd51c2d2516294c4e812a8e9313dfe86b" class="bill-dtd-OLC" pagenum="2"><num value="2">(2)</num><chapeau> review the impact or potential impact of controls on fentanyl-related substances on public health and safety, including on—</chapeau><subparagraph identifier="/s3/c/2/A" id="id3234554F76534EC885FE5422A6805330" class="bill-dtd-OLC" pagenum="2"><num value="A">(A)</num><content> diversion risks, overdose deaths, and law enforcement encounters with fentanyl-related substances; and</content></subparagraph><subparagraph identifier="/s3/c/2/B" id="id93aad27736094be9b29fcd2470e0cdb0" class="bill-dtd-OLC" pagenum="2"><num value="B">(B)</num><content> Federal law enforcement investigations and prosecutions of offenses relating to fentanyl-related substances;</content></subparagraph></paragraph><paragraph identifier="/s3/c/3" id="id669a4d4eb2474d1f918594c15a781f10" class="bill-dtd-OLC" pagenum="2"><num value="3">(3)</num><content> review the impact of international regulatory controls on fentanyl-related substances on the supply of such substances to the United States, including by the Government of the People’s Republic of China;</content></paragraph><paragraph identifier="/s3/c/4" id="idcb1f16103c1c4261b64df44e3ae75e70" class="bill-dtd-OLC" pagenum="2"><num value="4">(4)</num><content> review the impact or potential impact of screening and other interdiction efforts at points of entry into the United States on the importation of fentanyl-related substances into the United States;</content></paragraph><paragraph identifier="/s3/c/5" id="id1da8085003bf43aaba26cf25129d513b" class="bill-dtd-OLC" pagenum="2"><num value="5">(5)</num><chapeau> recommend best practices for accurate, swift, and permanent control of fentanyl-related substances, including—</chapeau><subparagraph identifier="/s3/c/5/A" id="ide078e6dd861a4383997db19cf67179b6" class="bill-dtd-OLC" pagenum="2"><num value="A">(A)</num><content> how to quickly remove from the schedules under the Controlled Substances Act substances that are determined, upon discovery, to have no abuse potential; and</content></subparagraph><subparagraph identifier="/s3/c/5/B" id="id76720bb008bc4c578b0cfbdae84902e6" class="bill-dtd-OLC" pagenum="2"><num value="B">(B)</num><content> how to reschedule substances that are determined, upon discovery, to have a low abuse potential or potential accepted medical use;</content></subparagraph></paragraph><paragraph identifier="/s3/c/6" id="idb6fa6028e115437b8dfe729e17da201e" class="bill-dtd-OLC" pagenum="2"><num value="6">(6)</num><content> review the impact or potential impact of fentanyl-related controls by class on scientific and biomedical research; and</content></paragraph><paragraph identifier="/s3/c/7" id="id380309502c2749a08489086dd1c6db60" class="bill-dtd-OLC" pagenum="2"><num value="7">(7)</num><chapeau> evaluate the processes used to obtain or modify Federal authorization to conduct research with fentanyl-related substances, including by—</chapeau><subparagraph identifier="/s3/c/7/A" id="idc3740c4abdc649f7b6268125275c54a4" class="bill-dtd-OLC" pagenum="2"><num value="A">(A)</num><content> identifying opportunities to reduce unnecessary burdens on persons seeking to research fentanyl-related substances;</content></subparagraph><subparagraph identifier="/s3/c/7/B" id="ide1e19ae73df645ecb7420d258cd1c767" class="bill-dtd-OLC" pagenum="2"><num value="B">(B)</num><content> identifying opportunities to reduce any redundancies in the responsibilities of Federal agencies;</content></subparagraph><subparagraph identifier="/s3/c/7/C" id="idb5726b7f1e884de49ddb9e42581e1202" class="bill-dtd-OLC" pagenum="2"><num value="C">(C)</num><content> identifying opportunities to reduce any inefficiencies related to the processes used to obtain or modify Federal authorization to conduct research with fentanyl-related substances;</content></subparagraph><subparagraph identifier="/s3/c/7/D" id="id212254A682D143E1A81897A073A643D6" class="bill-dtd-OLC" pagenum="2"><num value="D">(D)</num><content> identifying opportunities to improve the protocol review and approval process conducted by Federal agencies; and</content></subparagraph><subparagraph identifier="/s3/c/7/E" id="idf3e442c7aa9b483f83f33afdc4042129" class="bill-dtd-OLC" pagenum="2"><num value="E">(E)</num><content> evaluating the degree, if any, to which establishing processes to obtain or modify a Federal authorization to <?page 3?>conduct research with a fentanyl-related substance that are separate from the applicable processes for other schedule I controlled substances could exacerbate burdens or lead to confusion among persons seeking to research fentanyl-related substances or other schedule I controlled substances.</content></subparagraph></paragraph></subsection><subsection identifier="/s3/d" id="idc66b3545aa364549b262ef461263bf2e" class="bill-dtd-OLC" pagenum="3"><num value="d">(d)</num><heading> Input from certain Federal agencies.—</heading><content>In conducting the study and developing the report under subsection (b), the Comptroller General shall consider the views of the Department of Health and Human Services and the Department of Justice.</content></subsection><subsection identifier="/s3/e" id="idF2E2FD0D71C44BFB857AA8AF28661558" class="bill-dtd-OLC" pagenum="3"><num value="e">(e)</num><heading> Information from Federal agencies.—</heading><content>Each Federal department or agency shall, in accordance with applicable procedures for the appropriate handling of classified information, promptly provide reasonable access to documents, statistical data, and any other information that the Comptroller General determines is necessary to conduct the study and develop the report required under subsection (b).</content></subsection><subsection identifier="/s3/f" id="idd3f1d4dbbab44b25834edadbcf3ecad1" class="bill-dtd-OLC" pagenum="3"><num value="f">(f)</num><heading> Input from certain non-Federal entities.—</heading><chapeau>In conducting the study and developing the report under subsection (b), the Comptroller General shall consider the views of experts from certain non-Federal entities, including experts from—</chapeau><paragraph identifier="/s3/f/1" id="id20775fe2992044c3873f819b52f87a02" class="bill-dtd-OLC" pagenum="3"><num value="1">(1)</num><content> the scientific and medical research community;</content></paragraph><paragraph identifier="/s3/f/2" id="idafcd3b943c6444a98306112e5da77bc5" class="bill-dtd-OLC" pagenum="3"><num value="2">(2)</num><content> the State and local law enforcement community; and</content></paragraph><paragraph identifier="/s3/f/3" id="id8a6366b221184bbc83e3951e64d5f9c3" class="bill-dtd-OLC" pagenum="3"><num value="3">(3)</num><content> the civil rights and criminal justice reform communities.</content></paragraph></subsection></section></main><signatures><signature><name/><role>Speaker of the House of Representatives</role></signature><signature><name/><role>Vice President of the United States and President of the Senate</role></signature></signatures></bill>